<p>Shares of <strong>Hims &amp; Hers Health, Inc.</strong> (NYSE:HIMS) are trading higher on Thursday as investors react to a new chief medical leadership appointment. Here’s what investors need to know.</p>



<ul>
<li>Hims &amp; Hers Health stock is showing exceptional strength. Why is HIMS stock surging?</li>
</ul>



<h2>What Is Driving Hims &amp; Hers Health Stock Today?</h2>



<p>Hims &amp; Hers named <strong>Anant Vinjamoori</strong> as chief medical officer, highlighting his background in longevity medicine and preventive healthcare. The company also pointed to a medical leadership bench with more than 100 years of combined experience spanning weight loss, sexual health, hormone health, mental health, dermatology and primary care.</p>



<p>“Men increasingly want proactive, science-driven care to feel their best at every age, and Hims has the scale to deliver it,” Vinjamoori said.</p>



<p>Global CMO <strong>Pat Carroll</strong> added, “Dr. Vinjamoori’s clinical expertise is the perfect addition to help us bring the latest innovations in proactive health to our customers.”</p>



<h2>HIMS Stock: Critical Levels To Watch</h2>



<p>From a longer-term trend lens, HIMS is still in &#34;repair mode&#34;: it's down 44.81% over the past 12 months and remains below its 200-day SMA ($34.14), which keeps the bigger picture biased lower despite the rally. At the same time, the stock is trading above its 20-day SMA ($25.36), 50-day SMA ($24.59), and 100-day SMA ($23.76), which is the kind of base-building behavior you want to see before a more durable trend change.</p>



<p>MACD is the cleaner momentum read right now: it's above its signal line and the histogram is positive, which points to improving momentum versus the prior downswing (in plain English, MACD compares two moving averages, and being above the signal line suggests downside pressure is easing). The catch is the longer-term &#34;death cross&#34; from December 2025 (50-day SMA below the 200-day SMA) is still in place, so bulls typically want follow-through that starts reclaiming longer-term averages.</p>



<ul>
<li><strong>Key Resistance</strong>: $30.50 — a nearby round-number area where rebounds can stall before the longer-term trend fully improves</li>



<li><strong>Key Support</strong>: $28.00 — a nearby pivot zone that's close enough to matter if today's pop fades</li>
</ul>



<h2>What Is Hims &amp; Hers Health?</h2>



<p>Hims &amp; Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements.</p>



<p>The platform has more than 2 million subscribers and is available in all 50 states and certain European markets like the UK, with provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities.</p>



<h2>HIMS Stock Price Action On Thursday</h2>



<p><strong>HIMS Stock Price Activity:</strong> Hims &amp; Hers Health shares were up 7.23% at $29.50 at the time of publication on Thursday, according to Benzinga Pro data.</p>



<div>


<p>
<strong>
Read Also:

Space Stocks Bleed: Redwire, Momentus Down More Than 20% As SpaceX IPO Fatigue Hits
</strong>
</p>


</div>


<p><em>Image: Shutterstock</em></p>

HIMS

HIMZ

HIMY

<p>Hims & Hers Health (NYSE: HIMS) shares rose 7.23% to $29.50 following the appointment of Anant Vinjamoori as chief medical officer, highlighting his expertise in longevity and preventive care. While short-term momentum indicators show improvement with the stock trading above key short-term moving averages, the longer-term trend remains bearish due to a 'death cross' and significant year-to-date decline. Key technical levels include resistance at $30.50 and support at $28.00.</p>

Hims & Hers Stock Jumps: What's Happening Today?